illumicell AI

illumicell AI

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

illumicell AI is an early-stage, AI-driven diagnostics company operating out of the Harvard Pagliuca Life Lab. The company has developed a proprietary technology platform that uses AI to analyze cellular behavior, generating significantly more data than standard tests. Its initial focus areas are AI-powered semen analysis for fertility and immune cell activation readouts for immuno-oncology and autoimmune disease monitoring. The company raised a $2M pre-seed round in 2025 and is collaborating with Harvard on research studies.

FertilityOncologyAutoimmune Diseases

Technology Platform

Proprietary AI/ML platform that analyzes live cellular behavior to generate high-density data signatures for diagnostics and monitoring. Applications include computer vision for semen analysis and functional assays for immune cell activation.

Opportunities

The company operates in large, growing markets (fertility, immuno-oncology, autoimmune) where AI-enhanced precision diagnostics are in high demand.
Its asset-light platform model allows it to potentially service multiple verticals.
The Harvard affiliation provides significant research credibility and access to talent.

Risk Factors

The company is at an early stage with a broad focus, risking resource dilution.
It faces significant regulatory hurdles and requires extensive clinical validation for its AI models.
Competition in AI diagnostics is intense from both startups and established diagnostic firms.

Competitive Landscape

In fertility, competes with established manual lab services and new digital sperm analyzers (e.g., YO, Trak). In immune cell analysis, faces competition from large CROs (LabCorp, Q2 Solutions) and specialty labs adopting AI. In autoimmune monitoring, competes with large diagnostic companies and biopharma firms developing companion diagnostics.